Atlas Energy Corp reports financial results and corporate updates as an international upstream royalty and streaming company. The company focuses on the acquisition, management, and monetization of diversified oil and gas royalty and streaming interests across global markets. Its news also covers capital-structure actions and listing status, including its completed recapitalization, TSX Venture Exchange trading under ATLE, voluntary OTCQB delisting, and continued U.S. OTC Pink trading under CANSF.
Willow Biosciences (TSX: WLLW; OTCQB: CANSF) reported record Q2 2024 revenue of $1.0 million, a 600% increase year-over-year. The company signed a strategic partnership with Laurus Labs to develop biobased processes for seven high-value APIs, expecting $4.0 million in guaranteed R&D payments in the first year. Willow anticipates over $4 million in revenue for 2024 from existing programs. The company also closed a private placement raising $1,639,737 and initiated a new feasibility study for bioactive pesticides production. With strengthened AI and business development capabilities, Willow continues to focus on revenue growth and cost reduction.
Willow Biosciences has announced a significant partnership with Laurus Labs to develop and manufacture active pharmaceutical ingredients (APIs), expecting $4 million in guaranteed R&D payments in the first year and annual royalties upon commercialization. The company projects revenue of over $1 million for Q2 and $3.5 million for 2024. Willow has also ventured into biopesticides, securing a proof-of-concept agreement with a biotech firm. Additional appointments include Dr. Richard Fox as Senior Advisor for AI Platform Technologies and Mr. Gregory Rocklin for Business and Corporate Development. The company has recently secured its first patent and plans to file five more in 2024. Willow aims to reduce its monthly burn rate and is optimistic about signing 2-3 new programs by year-end.
Willow Biosciences has announced a major partnership with Laurus Labs to develop and license multiple pharmaceutical ingredients. This strategic alliance grants Laurus access to Willow's AI-driven bioengineering platform, targeting seven high-value APIs, including corticosteroids. This partnership is Willow's largest to date, projected to generate significant annual revenues, with $4 million guaranteed in the first year for research and development. Willow's technology will help Laurus produce more sustainable and cost-effective APIs. Both companies anticipate commercial manufacturing to begin in 2025.
Willow Biosciences Inc. reported its first quarter 2024 financial results, showcasing reduced costs and progress in commercial expansion. The company continues to advance its corticosteroid production platform and expects to sign a large strategic partnership in Q2 2024. Willow signed new program agreements, advanced three programs, and aims to double its 2024 revenues. Financially, the company reduced cash burn by 53% compared to the previous year, ending the quarter with $1.6 million in cash.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.